Tags: cicc , healthcare

Equities

Shanghai Pharma raises $2 billion from Hong Kong listing

China's second-biggest drug distributor prices its H-share offering below the mid-point, but at a modest 2.4% discount versus its A-shares.

By Anette Jönsson | 16 May 2011

Equities

Shanghai Pharma braves weak market with $2.2 billion IPO

Shanghai Pharma's IPO beats the odds to find good demand in difficult market conditions.

By Lillian Liu | 4 May 2011

Equities

Concord Medical prices IPO near top, but falls on debut

The operator of cancer treatment centres avoids the fate of two other Chinese listing candidates which were forced to re-price or pull their US IPOs, but the stock still slumps ...

By Anette Jönsson | 14 December 2009

Equities

Chinese cancer treatment company aims for US listing

Concord Medical Services aims to raise up to $138 million from an IPO and is expected to start trading on the NYSE late next week.

By Anette Jönsson | 3 December 2009

Equities

Massive demand for Sinopharm bodes well for IPO pipeline

The Chinese pharmaceutical distributor prices at the top to raise $1.13 billion after attracting $110 billion worth of orders. Separately, Digital China raises $49 million from ...

By Anette Jönsson | 17 September 2009

Equities

Sinopharm sets price range for $1.13 billion IPO

The Chinese distributor of pharmaceutical products will be the first company to take orders for a Hong Kong listing after the summer and has set the price range at HK12.25 to ...

By Anette Jönsson | 4 September 2009

Equities	Debt
M&A	Moves People Moves Business Moves
News & Views View Point Macro & Markets Corporate	Banking Structured Products FX Private Banking
Editor's Desk Awards Co-published Editor's Desk Polls Book Review Private Capital	Conference Highlights
CorporateTreasury Cash Trade CorporateTreasury Moves Risk	Magazine Highlights

Tags: cicc, healthcare

Tags: cicc , healthcare